AbbVie completes acquisition of Aliada Therapeutics to enhance neuroscience development
12/11/24, 3:06 PM
Location
north chicagobostonIndustry
biotechnology
AbbVie completed the acquisition of Aliada Therapeutics, a company focused on the development of therapeutic solutions for Alzheimer's disease. With this acquisition, AbbVie aims to advance potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolster their neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform.
Company Info
Location
North Chicago, Illinois, United States
Company info
Cerevel Therapeutics is a biopharmaceutical company dedicated to developing therapies for neuroscience. It focuses on curing diseases associated with the central nervous system, specializing in treating disorders such as schizophrenia and epilepsy. Cerevel is known for its innovative approaches to complex neurological conditions. The company went public and was listed on NASDAQ under the ticker symbol CERE.
Related People
New Feature: Generate AI-Powered Emails Instantly!
Use one of the following options:
- Click the AI button next to your contact's email to generate a draft automatically.
- Use Copy to Clipboard to paste the email into your favorite email service.
- Click Send via Webmail to use Gmail or another online client.
Important: If nothing happens when you click, you might not have a default email client set up.